Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

US Flu Vaccine a Good Match in Moderate Season So Far

By Mike Stobbe, AP Medical Writer | February 22, 2017

This season’s flu vaccine seems to be working pretty well, weakening the punch of a nasty bug that’s going around, U.S. health officials said Thursday.

Preliminary figures suggest the vaccine is 48 percent effective. That’s not bad since the strain that’s making most people sick is one of the worst. Experts consider it a good year when a flu vaccine is 50 to 60 percent effective.

“We’re happy” so far this year, said Dr. Alicia Fry, a flu expert at the Centers for Disease Control and Prevention.

The flu vaccine is changed each year based on the best guess at which three or four strains will be the biggest problem for the next season. The current vaccine is a good match, and includes a strain of Type A H3N2 flu virus that is causing most illnesses.

That wasn’t the case with the vaccine two years ago when the same bug dominated and caused a very bad flu season.

Flu usually peaks in midwinter. Cases are escalating in some parts of the country, like the Midwest, but already receding in others, like the Northwest. Fry characterized the current flu season as moderate.

Flu shots are recommended for virtually all Americans age 6 months or older. Health officials were worried that fewer kids would get vaccinated this season after they stopped endorsing a popular nasal spray version. Research showed it didn’t work well for another common type of flu. But vaccination rates for kids by November were about the same as the year before, Fry said.

Among infectious diseases, flu is considered one of the U.S.’s leading killers. CDC estimates suggest that in an average year, about 35,000 Americans die from flu-related causes. The CDC calculates effectiveness from a sample of flu tests done in five states.


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE